Securities Code: 002653
Securities Abbreviation: Haisco
Announcement No.: 2026-063
Haisco Pharmaceutical Group Co., Ltd.
Announcement on Signing the HSK42360 and HSK39297 License Agreements with Nuvectis
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, without any false records, misleading statements, or material omissions.
Risk Warning:
The upfront payments and milestone payments stipulated in the license agreements signed this time are subject to certain conditions, and the final implementation of the transaction remains uncertain.
Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Haisco" or the "Company") and Nuvectis Pharma, Inc. (hereinafter referred to as "Nuvectis") have recently signed an exclusive license agreement (hereinafter referred to as the "License Agreement"), granting Nuvectis the exclusive right to develop, produce, and commercialize the HSK42360 project (BRAF inhibitor) globally, excluding the Greater China region. It also grants Nuvectis the exclusive right to develop, produce, and commercialize the HSK39297 project (CFB inhibitor) globally, excluding the Greater China, Southeast Asia, and India regions. As part of the consideration for the out-licensing transaction, the Company will receive license fees from Nuvectis for the HSK42360 and HSK39297 projects (including an upfront payment of $40 million and near-term milestone payments, and additional milestone payments of up to $1.421 billion) as well as sales royalties.